April 2025 Nordic Pharma received CE Mark approval for LACRIFILL®, expanding the availability of its canalicular gel technology for the treatment of dry eye disease across European markets.
February 2025 Alcon commercially launched the Voyager™ Direct Selective Laser Trabeculoplasty (DSLT) system in the U.S., expanding its ophthalmic treatment portfolio with an automated device for glaucoma and ocular hypertension.
January 2025 Alcon launched the UNITY® Vitreoretinal Cataract System (VCS) and UNITY® Cataract System (CS), expanding its ophthalmic surgical platform with next-generation technologies supporting advanced eye procedures.